SRPT241115C147000
- 0.00
- 0.000.00%
Sarepta Therapeutics Newsroom
Statutory Earnings May Not Be The Best Way To Understand Sarepta Therapeutics' (NASDAQ:SRPT) True Position
Why Sarepta Therapeutics' (NASDAQ:SRPT) Earnings Are Weaker Than They Seem
Sarepta's Valuation Seen As An Easy Pill to Swallow -- Market Talk
J.P. Morgan Maintains Sarepta Therapeutics(SRPT.US) With Buy Rating
Analysts Offer Insights on Healthcare Companies: Sarepta Therapeutics (SRPT) and DocGo (DCGO)
Notable Analyst Calls This Week: Carvana, Devon Energy and Palantir Among Top Picks
Barclays Maintains Sarepta Therapeutics(SRPT.US) With Buy Rating, Maintains Target Price $209
Mizuho Securities Maintains Sarepta Therapeutics(SRPT.US) With Buy Rating
A Quick Look at Today's Ratings for Sarepta Therapeutics(SRPT.US), With a Forecast Between $150 to $209
Sarepta Therapeutics: Strong Elevidys Sales Drive Buy Rating Amid Portfolio Optimism and Favorable Valuation
Sarepta Therapeutics Price Target Cut to $193.00/Share From $200.00 by Baird
Sarepta Therapeutics Is Maintained at Outperform by Baird
Express News | Evercore ISI Group Maintains Outperform on Sarepta Therapeutics, Lowers Price Target to $170
Sarepta Therapeutics To Rally Around 30%? Here Are 10 Top Analyst Forecasts For Thursday
Sarepta Therapeutics Shares Are Trading Higher After the Company Reported Better-than-expected Q3 Financial Results. Also, Cantor Fitzgerald Upgraded the Stock From Neutral to Overweight and Raided Its Price Target From $152 to $167.
A Quick Look at Today's Ratings for Sarepta Therapeutics(SRPT.US), With a Forecast Between $167 to $210
This McKesson Analyst Turns Bullish; Here Are Top 5 Upgrades For Thursday
Sarepta Therapeutics Raised to Overweight From Neutral by Cantor Fitzgerald
RBC Capital Reaffirms Their Buy Rating on Sarepta Therapeutics (SRPT)
Express News | Needham Reiterates Buy on Sarepta Therapeutics, Maintains $205 Price Target